|
|
|
|
| LEADER |
01475nam a2200241 u 4500 |
| 001 |
EB002010932 |
| 003 |
EBX01000000000000001173831 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
220201 r ||| eng |
| 245 |
0 |
0 |
|a Clinical review report: Eculizumab (Soliris)
|h Elektronische Ressource
|b Alexion Pharma Canada corporation : indication : adult patients with generalized myasthenia gravis
|
| 246 |
3 |
1 |
|a Eculizumab (Soliris)
|
| 250 |
|
|
|a Version: Final (with redactions)
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c 2020, December 2020
|
| 300 |
|
|
|a 1 PDF file (97 pages)
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH common drug review
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK567510
|3 Volltext
|
| 082 |
0 |
|
|a 140
|
| 520 |
|
|
|a The objective of this report is to perform a systematic review of the beneficial and harmful effects of eculizumab for the treatment of adult patients who are AChR-antibody-positive and have refractory generalized myasthenia gravis, defined as having failed treatment with at least two immunosuppressive therapies (ISTs), either in combination or as monotherapy, or having failed at least one IST and requiring chronic plasma exchange or intravenous immunoglobulin to control sympto02ms
|